Dr. Logan Discusses Treatment Options in CLL
Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL).
CLL remains the most common leukemia in adults, says Logan. This has led to a lot of innovative therapy, such as monoclonal agents and chemoimmunothearpy.
Additionally, patients with genetic abnormalities such as 17p deletion and p53 now have targeted agents like venetoclax (Venclexta), as these mutations do not respond well to chemoimmunotherapy.